Publisher： Bentham Science Publishers
E-ISSN： 2212-2710|8|2|85-91
ISSN： 1872-213X
Source： Recent Patents on Inflammation & Allergy Drug Discovery, Vol.8, Iss.2, 2014-05, pp. : 85-91
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
The hepatitis C virus (HCV) is a prevalent human pathogen that causes persistent liver infections in most infected individuals; thus, efforts to develop a safe vaccine, preventive and therapeutic, are urgently needed. Current approaches for the vaccine include the use of recombinant E1 and E2 proteins, synthetic peptides, viral particles, viral vectors, DNA vaccines, dendritic cells, and prime-boost strategies. However, several problems have been encountered: restricted humoral and cell mediated responses, the low delivery of potentially protective viral epitopes, and the low effectiveness of the adjuvants used in the different protocols. Strong neutralizing antibodies and powerful cellular immune responses are required for an effective vaccine against HCV. New patents are being developed to enhance both immune responses. The high prevalence of global HCV infection obliges the development of new efforts in primary prevention; therefore, a safe and efficient vaccine to confer protection against HCV is urgently needed.
Related content
Recent Patents on Influenza Vaccines
Recent Patents on Biotechnology, Vol. 1, Iss. 3, 2007-11 ,pp. :
Access to resources
Recommend
Peptide Vaccines for Cancer Therapy
Recent Patents on Inflammation & Allergy Drug Discovery, Vol. 9, Iss. 1, 2015-04 ,pp. :
Vaccines for Patients with COPD
Recent Patents on Inflammation & Allergy Drug Discovery, Vol. 9, Iss. 1, 2015-04 ,pp. :
Editorial (Thematic Issue: Vaccines)
Recent Patents on Inflammation & Allergy Drug Discovery, Vol. 9, Iss. 1, 2015-04 ,pp. :
Recent Developments in Particulate-Based Vaccines
Recent Patents on Drug Delivery & Formulation, Vol. 1, Iss. 2, 2007-06 ,pp. :